Overview
- Editors:
-
-
Michael A. Linden
-
and Pathology, University of Minnesota Department of Laboratory Medicine, Minneapolis, USA
-
Robert W. McKenna
-
and Pathology, University of Minnesota Department of Laboratory Medicine, Minneapolis, USA
Provides a concise yet comprehensive summary
Written by experts in the field
Richly illustrated with extensive color figures
Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (8 chapters)
-
-
-
- Rajeevan Selvaratnam, Jing Cao, Amy B. Karger
Pages 25-42
-
- Garth Aasen, Robert W. McKenna
Pages 43-64
-
-
-
- Beenu Thakral, Kristy Wolniak, Michael A. Linden
Pages 101-122
-
- Brian L. McClune, Sagar S. Patel
Pages 123-141
-
- Elizabeth L. Courville, Zohar Sachs, Michael A. Linden
Pages 143-149
-
Back Matter
Pages 151-152
About this book
This textbook will provide a comprehensive, state-of-the art review the field of diagnostic hematopathology as it’s applied to patients with plasma cell neoplasms. Particular emphasis will be placed on immunophenotypic data – immunohistochemistry and flow cytometry – as well as cytogenetics. We will also discuss how these ancillary data can predict prognosis and chemotherapeutic response. Plasma Cell Neoplasms will serve as a very useful resource for physicians and researchers interested in the plasma cell myeloma diagnosis, therapy, and research. It will provide a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters will be written by experts in their fields and will include the most up to date scientific and clinical information.
About the editors
Dr. Linden is an Assistant Professor in the Division of Hematopathology within the Department of Laboratory Medicine and Pathology. In addition, he is the Assistant Director of the Special Hematology Laboratory. As a graduate student, Dr. Linden’s thesis work helped develop a new mouse model of multiple myeloma. Dr. Linden completed residency and fellowship training in Hematopathology at the University of Washington. He now attends on the University of Minnesota Medical Center’s Hematopathology and Flow Cytometry services. Dr. Linden continues to have a strong interest in plasma cell and other hematopoietic neoplasms and enjoys research that applies his clinical skills to improving clinical laboratory diagnoses and predicting clinical outcomes. More specifically, he is investigating optimum diagnostic methods for monitoring residual disease in myeloma patients and developing diagnostic tests to predict chemotherapeutic sensitivity of the neoplastic plasma cells. In addition, he greatly values resident/fellow education and mentorship.
